Anterior pituitary gland disorder
MONDO:0024468A disease that involves the adenohypophysis.
Also known as: adenohypophysis disease, adenohypophysis disease or disorder, disease of adenohypophysis, disease or disorder of adenohypophysis, disorder of adenohypophysis, disorder of anterior pituitary, disorder of anterior pituitary gland
60 clinical trials for this condition and its sub-types, 1 tagged with Anterior pituitary gland disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Anterior pituitary gland disorder
-
Hyperpituitarism 0 trials · 59 incl. sub-types
4 sub-types
- Acromegaly 29 trials
- ACTH-dependent Cushing syndrome 23 trials · 26 incl. sub-types Sub-types →
- Hyperprolactinemia 9 trials Sub-types →
- Pituitary gigantism 4 trials
-
Adenohypophysitis 0 trials
Most studied deeper sub-types
-
New drug combo aims to tame acromegaly hormone levels
Disease control Stopped earlyThis phase 2 trial tests whether adding ALXN2420 (a growth hormone blocker) to standard acromegaly treatment can lower IGF-1 levels more than placebo. About 60 adults with acromegaly who are already on a stable dose of somatostatin analogs will receive either ALXN2420 or placebo …
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill shows promise for controlling acromegaly Long-Term
Disease control Stopped earlyThis study looks at the long-term safety and effectiveness of an oral medication called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. About 43 adults who finished a previous related study will take the drug and be monitored for …
Phase 2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a pill replace needles for acromegaly?
Disease control Stopped earlyThis study tests an oral drug called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. Participants had their disease under control with standard injections and were randomly assigned to receive either paltusotine or a placebo. The …
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill could tame rare growth disorder without surgery
Disease control Stopped earlyThis study tests an oral drug called paltusotine in 111 adults with acromegaly, a condition causing abnormal growth due to high hormone levels. Participants are not currently on other treatments. The main goal is to see if the drug safely lowers insulin-like growth factor-1 (IGF-…
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New 12-Week hormone therapy studied for rare tumors
Disease control Stopped earlyThis early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to me…
Phase 1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC